232 MODERN BIOLOGIC THERAPEUSIS 



weeks. Therefore, it has not been possible here- 

 tofore to market Pollen Vaccine commercially. 

 By experimentation with different means of ex- 

 tracting the pollen, a method has been evolved 

 in our laboratories of making the extraction in 

 glycerin and salt which yields a vaccine that 

 has been demonstrated to remain stable without 

 any detectable loss in potency for a period long- 

 er than the time required to administer the com- 

 plete prophylactic treatment. 



In the preparation of Pollen Vaccine, the pol- 

 len from the various common grasses, weeds 

 and other flowering plants which cause hay fever 

 in the spring and in the fall, have been combined. 

 The correct amounts of vaccine for the various 

 doses are supplied in individual vials serially 

 numbered, each vial containing approximately 

 one-tenth cubic centimeter of the vaccine. Be- 

 fore administration, the vaccine must be diluted, 

 with the diluent which is furnished in a separate 

 vial; but this final dilution should not be made 

 until immediately before administration of the 

 vaccine. 



Dosage and Administration The prophylac- 

 tic treatment consists of 15 doses of Pollen Vac- 

 cine administered subcutaneously in the ab- 



